Format

Send to

Choose Destination
Mol Imaging Biol. 2016 Oct;18(5):705-14. doi: 10.1007/s11307-016-0936-y.

Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin.

Author information

1
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, PO BOX 9101, 6500 HB, Nijmegen, The Netherlands. Stefanie.willekens@radboudumc.nl.
2
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, PO BOX 9101, 6500 HB, Nijmegen, The Netherlands.
3
ULB Center for Diabetes Research, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Abstract

PURPOSE:

Noninvasive beta cell mass (BCM) quantification is a crucial tool to understand diabetes development and progression. [(111)In]exendin is a promising agent for in vivo beta cell imaging, but tracer testing has been hampered by the lack of well-defined rodent models.

PROCEDURES:

Biodistribution and pancreatic uptake of [(111)In]exendin were compared in rats and mice. In selected models, the amount of [(111)In]exendin accumulation in the pancreas and other organs was determined using a model of alloxan-induced beta cell loss. GLP-1R expression levels were analyzed by RT-PCR and immunohistochemistry.

RESULTS:

Namely Brown Norway rats showed beta-cell-specific tracer accumulation and favorable pancreas-to-background ratios for noninvasive BCM determination. Mice displayed receptor-mediated [(111)In]exendin uptake in endocrine and exocrine pancreas, in spite of very low GLP-1R expression in exocrine tissue.

CONCLUSIONS:

Rats display better characteristics for in vivo BCM determination than mice and are suggested as a more adequate model for humans.

KEYWORDS:

Beta cell mass; Diabetes; Exendin; GLP-1R; Receptor targeting

PMID:
26886298
PMCID:
PMC5010585
DOI:
10.1007/s11307-016-0936-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center